FDA authorizes AstraZeneca’s monoclonal antibodies for some who can’t get vaccinated or are immunocompromised


U.S.-listed shares of AstraZeneca AZN, +0.68% were up 0.3% in after-hours trading on Wednesday after the Food and Drug Administration authorized the company’s COVID-19 monoclonal antibodies for pre-exposure prophylaxis in individuals who are immunocompromised or have a history of severe adverse reactions to a COVID-19 vaccine. In both instances, the individuals, who must be at least 12 years old, may not be able to gain protective antibodies through COVID-19 vaccination. This is the first authorization for a pre-exposure prophylaxis therapy in the U.S., though the FDA has already authorized some monoclonal antibodies for post-exposure prophylaxis. AstraZeneca’s therapy, Evusheld, pairs two monoclonal antibodies, to be given in separate injections. It may be effective for six months, the FDA said. AstraZeneca’s stock is up 10.3% so far this year, while the broader S&P 500 SPX, +0.31% has gained 24.8%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Viruses like parties — doctors who specialize in infectious diseases give their verdict on New Year’s Eve
Next articleStocks close modestly higher again Wednesday, extending the week’s rally


Please enter your comment!
Please enter your name here